Hadean Ventures leads Kasvu Therapeutics’ €30 million Series A round
Kasvu Therapeutics raised a EUR 30 million Series A round led by Hadean Ventures to advance its TrkB potentiator program. Kasvu develops small-molecule TrkB positive allosteric modulators designed to boost neuroplasticity without 5-HT2A-driven hallucinogenic effects. Proceeds will fund IND/CTA-enabling work for lead as